Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 11Cisplatin 11Biopsy 7Radiotherapy 6Immunohistochemistry 6Carboplatin 6pembrolizumab 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Cetuximab 5Trastuzumab 4Paclitaxel 4Nivolumab 4Gemcitabine 4Chemotherapy, Adjuvant 4Capecitabine 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Ipilimumab 3Goserelin 3Fluorodeoxyglucose F18 3Everolimus 3Erlotinib Hydrochloride 3sacituzumab govitecan 2pyrotinib 2pertuzumab 2bicalutamide 2Taxes 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Salivary Gland Neoplasms × talactoferrin alfa × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡